Compugen Ltd. (CGEN) Cash Flow Statement

The wide divergence between net income and operating cash flow suggests that accounting-based profitability is a poor proxy for the company's true liquidity position. Investors should monitor this gap closely, as it highlights that the firm's operational reality is defined by cash-intensive R&D rather than the accounting gains recognized from milestone-based revenue.

The lack of consistent positive free cash flow suggests that the company remains in a capital-consuming phase of its lifecycle. The absence of sustained FCF generation implies that the firm's valuation is likely driven by the potential for future milestone payments rather than current operational self-sufficiency.

The low level of capital expenditure appears to be a strategic choice, allowing the firm to preserve its cash runway for R&D. This asset-light model is appropriate for a discovery-stage biotech, though it warrants further investigation into whether this under-investment in infrastructure could limit future commercialization capabilities.

The decision to return capital to shareholders while the core business remains cash-flow negative suggests a management focus on share price support. Investors should monitor whether this deployment strategy compromises the company's ability to fund its long-term clinical pipeline without resorting to dilutive equity financing.